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Prudent prescribing of antimicrobial drugs to hospital
inpatients may reduce incidences of antimicrobial drug
resistance and healthcare-associated infection. We
reviewed the literature from January 1980 to November
2003 to identify rigorous evaluations of interventions to
improve hospital prescribing of antimicrobial drugs. We
identified 66 studies with interpretable data, of which 16
reported 20 microbiologic outcomes: gram-negative resist-
ant bacteria, 10 studies; Clostridium difficile–associated
diarrhea, 5 studies; vancomycin-resistant enterococci, 3
studies; and methicillin-resistant Staphylococcus aureus, 2
studies. Four studies provided strong evidence that the
intervention changed microbial outcomes with low risk for
alternative explanations, 8 studies provided less convincing
evidence, and 4 studies provided no evidence. The
strongest and most consistent evidence was for C. diffi-
cile–associated diarrhea, but we were able to analyze only
the immediate impact of interventions because of nonstan-
dardized durations of follow-up. The ability to compare
results of studies could be substantially improved by stan-
dardizing methods and reporting.
D
espite strenuous efforts to control antimicrobial drug
use and promote optimal prescribing, practitioners
continue to prescribe excessively; it is estimated that up to
50% of antimicrobial drug use in hospitals is inappropriate
(1–3). Antimicrobial drug resistance is largely a conse-
quence of the selective pressures of antimicrobial drug use.
Reducing these pressures by the judicious administration
of these drugs should facilitate a return of susceptible bac-
teria or, at least, prevent or slow the pace of the emergence
of drug-resistant strains (4,5). Furthermore, Clostridium
difficile–associated diarrhea (CDAD) is a hospital-
acquired infection associated with use of antimicrobial
drugs (6–8) and reducing the incidences of CDAD is an
additional potential benefit of improving hospital antimi-
crobial drug prescribing. 
Implementing and monitoring interventions to optimize
prescribing of antimicrobial drugs place a burden on hos-
pital resources and their efficacies need to be confirmed
(9). We have conducted a systematic review of interven-
tions to improve antimicrobial drug–prescribing practices
for hospital inpatients using the methods of the Cochrane
Effective Practice and Organization of Care Group to
assess validity (10). In this study, our primary objective
was to evaluate the impact of interventions on reducing the
incidence of colonization with or infection caused by
antimicrobial drug–resistant pathogens or CDAD. In addi-
tion to the usual threats to the validity of interventions to
change health care, infection control interventions are par-
ticularly prone to regression to the mean (11). This refers
to the natural tendency of extreme observations to return
towards the average (mean) over time. An epidemic or out-
break is a sequence of unusually large number of cases of
infection, so that the natural history of an epidemic is to
increase, peak, and then decrease. Consequently, regres-
sion to the mean is always a threat to the validity of eval-
uations of unplanned interventions that are initiated in
response to an outbreak. 
Methods
The full protocol is available in the Cochrane Library
(10). We searched Medline, EMBASE, the Cochrane data-
base, and the Effective Practice and Organisation of Care
specialized register for studies from January 1, 1980, to
November 30, 2003, relating to prescribing of antimicrobial
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and ***University of Leeds, Leeds, United Kingdomdrugs to hospital inpatients. Additional studies were
obtained from the bibliographies of retrieved articles, the
Scientific Citation Index, and personal files. We requested
additional data from the authors when necessary. There
were no language limitations for the literature review. We
included all randomized and controlled clinical trials
(RCT/CCT, designs where allocation to the intervention is
determined either by an explicit random process [RCT] or
by a nonrandom process such as date of birth or case note
number) before and after studies (a design with contempo-
raneous data collection before and after the intervention and
an appropriate control site or activity) and interrupted time
series (ITS, a clearly defined point in time when the inter-
vention occurred and at least 3 data points before and 3 after
the intervention). Data about microbiologic outcomes were
considered reliable if they met the same criteria. For exam-
ple, if a paper included prescribing data that met the criteria
for an ITS but provided only mean data about microbiolog-
ic outcomes before and after the intervention, then the
microbiologic data were not considered reliable. Two
reviewers independently extracted data and assessed the
quality of each study with the standardized criteria.
Statistical Considerations
Many statistical methods can be used to analyze ITS
designs (e.g., ARIMA modeling or time series regression).
However, the design is often analyzed inappropriately,
which makes interpretation of individual studies difficult
(12). Methods of analyzing ITS data were examined criti-
cally (12). The preferred method for short time series is
segmented time series regression analysis, which is a sta-
tistical comparison of time trends before and after the
intervention to identify either an immediate change in the
level of the regression line or a sustained change in the
slope of the line (12,13). In this report, we have distin-
guished 2 intervention effects: immediate (a sudden
change in the level of the regression line at the point of
intervention) and sustained (a sustained change in the
slope of the regression line from the start of the interven-
tion phase). If the original report did not include an appro-
priate analysis, data were reanalyzed by using segmented
time series regression. 
The following model was specified: Yt = B0 + B1 × pres-
lope + B2 × postslope + B3 × intervention + et, where Yt is
the outcome (e.g., CDAD incidence) in month t, preslope
is a continuous variable indicating time from the start of
the study up to the last point in the preintervention phase
and coded constant thereafter, postslope is coded 0 to and
including the first point postintervention and coded
sequentially from 1 thereafter, and intervention is coded 0
for preintervention time points and 1 for postintervention
time points. In this model, B1 estimates the slope of the
preintervention data, B2 estimates the slope of the postin-
tervention data, and B3 estimates the change in level of out-
come as the difference between the estimated first point
postintervention and the extrapolated first point postinter-
vention if the preintervention line was continued into the
postintervention phase. The difference in slope is calculat-
ed by B2 – B1. The error term et was assumed to be first-
order autoregressive. Confidence intervals (95%) were
calculated for all effect measures.
Formal metaanalysis of results was not attempted given
the differences in context, setting, and type of outcomes.
However, to gain an overall summary picture of the hetero-
geneity of effect sizes we standardized all measures so that
they were all on the same scale. To do this, we divided the
change in level and the change in slope by the preinterven-
tion standard deviation (SD) in each study. The resulting
metric has no unit, it is known in standard metaanalysis as
the standardized mean difference. Standardized effect sizes
of 2 to 3 SD were considered large, whereas an effect size
<0.5 SD was considered of questionable clinical signifi-
cance even if statistically significant (14). To visually dis-
play the heterogeneity of the standardized effect sizes,
graphic plots of level effects versus slope effects for each
study (with associated 95% confidence intervals) were
generated.
Other Criteria for Assessing Evidence
The statistical analysis assessed how likely it was that
study results could simply have happened by chance, and
the Cochrane quality criteria assessed common threats to
the validity of interventions to change practice or organi-
zation of care. To assess other threats to the validity of
infection control interventions, we used the format for
reporting the results of included studies recommended by
guidelines derived from a recent systematic review of iso-
lation measures to control methicillin-resistant
Staphylococcus aureus (MRSA) (15). We required studies
to provide reliable data about the effect of interventions on
both microbial and drug outcomes with clear case defini-
tion, description of infection control measures, and other
variables such as bed occupancy or staffing levels that
could provide plausible alternative explanations for
changes in microbial outcomes. We have provided a sum-
mary of detailed information from the included studies
(online Appendix Table, available from http://www.cdc.
gov/ncidod/EID/vol12no02/05-0145.htm#apptable).
Additional information is available from the British
Society for Antimicrobial Chemotherapy (www.bsac.
org.uk). We classified case definitions into colonization,
infection or clinical isolates, or a combination of >2 with
the following definitions. 
Colonization was defined as a microorganism, usually
detected by screening, at a host site (normally nonsterile,
although the urine of a catheterized patient may be an
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specific immune response. Colonization by case note
review was established by excluding infection diagnosed
according to criteria adopted by the authors or defined by
appropriate bodies, e.g., the Centers for Disease Control
and Prevention criteria for diagnosing nosocomial infec-
tions. Infection was established by case note review
according to criteria adopted by the authors or defined by
appropriate bodies or by recording specific symptoms
and/or signs, such as diarrhea in patients with CDAD.
Clinical isolates were defined as the recovery of a microor-
ganism after culture of a clinical (not screening) specimen
without specifying whether it represents colonization or
infection.
Results
We identified 66 intervention studies to improve pre-
scribing of antimicrobial drugs to hospital inpatients that
met our inclusion criteria (16) and excluded 243 studies
that were uncontrolled before and after studies (n = 164) or
inadequate ITS studies (n = 79). Of the 66 studies, 16
reported reliable data about 20 microbiologic outcomes:
gram-negative resistant bacteria (GNRB), 10 studies;
CDAD, 5 studies; vancomycin-resistant enterococci
(VRE), 3 studies; and MRSA, 2 studies (online Appendix
Table). The setting for the intervention was the entire hos-
pital in 8 studies (17–24), a single service in 2 studies
(25,26), and a unit or ward in 6 studies (27–32). One inter-
vention was educational with advice about changes in
antimicrobial drugs (17); the other 15 interventions were
restrictive (online Appendix Table). Two studies were
RCTs (31,32) and 1 study was a CCT (30); the remaining
13 studies used an ITS design.
Statistical Validity
All 3 clinical trials reported appropriate statistical
analysis (30–32), whereas only 2 of the 13 ITS studies
reported appropriate statistical analysis (17,27). Of the
remaining 11 ITS studies, 5 did not report statistical analy-
sis; 6 reported inappropriate statistical analysis by using
tests such as χ2 or  t tests that assume independence
between observations and do not account for time trends.
Data from these 11 studies were reanalyzed. 
Effectiveness of Interventions
Overall, 4 studies provided strong evidence of control
of the microbial outcome by change in prescribing
(17,27,30,31). All of these studies provided reliable data
about antimicrobial drug prescribing, with significant
changes in both microbial and drug outcomes after planned
interventions. In addition, 2 studies provided further pro-
tection against regression to the mean by using a crossover
design (27,30). Three of these studies have rigorous case
definitions based on prospective screening cultures plus
full description of infection control measures. 
Eight studies provided less convincing evidence. Two
studies showed significant changes in prescribing that
were associated with nonsignficant changes in CDAD
(20,26). An additional 6 studies reported statistically sig-
nificant improvement in microbial outcome but without
reliable data about the effect of the intervention on pre-
scribing (18,19,23,24,28,29). The importance of this omis-
sion is confirmed by the 6 studies that included reliable
data about prescribing because all showed that there was
some prescription of restricted drugs during the interven-
tion phase (17,20,26,27,30,31)
Four studies had negative results (21,22,25,32). One
study provided strong evidence of failure to control micro-
bial outcomes despite a successful change in prescribing
(32). One study reported an intervention that failed to
change use of vancomycin (22). The remaining 2 studies
showed no change in microbial outcome but did not pro-
vide reliable data about the effect of the intervention on
prescribing (21,25). 
CDAD
The most consistent evidence was for the 5 interven-
tions designed to reduce the incidence of CDAD. Four
were implemented throughout the hospital (17,18,20,24)
and 1 was implemented in the elderly care service (26); all
5 targeted prescribing of cephalosporin or clindamycin. All
of the interventions were associated with a change in the
expected direction (Figure part A), which was a change in
the incidence of CDAD in the same direction to a change
in use of cephalosporin or clindamycin. For 1 intervention,
the expected direction was an increase in CDAD incidence
after the introduction of ceftriaxone (20); for all other
interventions a decrease in CDAD incidence was expected
to accompany a decrease in use of cephalosporin or clin-
damycin. These 5 studies reported 7 interventions. The
immediate effect after 6 of the 7 interventions was at least
0.5 SDs; 5 of these 7 immediate effects were statistically
significant (Figure part A). Sustained changes after the
intervention were more modest, but all were in the expect-
ed directions and 4 of 7 were statistically significant
(Figure part A.). The 5 CDAD studies had results
expressed in different units: cases per month (24,26); cases
per quarter (18,20); or cases per 1,000 admissions per year
(17). Consequently, we were only able to compare effect
sizes in numbers of CDAD cases per quarter by recalculat-
ing results from 2 studies (24,26). The antimicrobial drug
intervention was associated with a mean immediate reduc-
tion of 15.0 CDAD cases per quarter (range 6–26) and a
median sustained reduction of 3.2 CDAD cases per quarter
(range 1–6). 
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The results of the 10 interventions designed to reduce
the incidences of GNRB were less consistent. Three were
implemented throughout the hospital (19,21,23), 1 was
implemented in the neurology and neurosurgery service
(25), and 5 were implemented in a single intensive care unit
(ICU), which included 4 with pediatric patients (28–30,32)
and 1 with adult patients (31). One intervention was
designed to reduce the duration of treatment with any
antimicrobial drug for ICU patients at low risk for pneumo-
nia; this was associated with a significant reduction in the
incidence of colonization by any GNRB and exposure to
antimicrobial drugs (31). The remaining 9 interventions
involved changes in antimicrobial drug treatment, mainly
aminoglycosides or cephalosporins. One RCT provided no
evidence that antimicrobial drug cycling reduced the inci-
dence of GNRB in a neonatal ICU (32). The 8 ITS studies
reported 9 outcomes (Figure part B). The expected direc-
tion of effect from a change in aminoglycoside or
cephalosporin prescribing was usually a reduction in
GNRB. For 1 intervention, the expected direction of effect
was an increase in the incidence of GNRB after gentamicin
was reintroduced (19). The expected direction for all 9 out-
comes changed, but the effect size was <0.5 SD in 2 stud-
ies and not statistically significant in 5 studies (Figure part
B). In 3 studies the changes in slope were in the expected
direction and in 1 the changes were both statistically signif-
icant and >0.5 SD, which is likely clinically important.
Unlike with CDAD data, effects cannot be expressed in a
common unit. Some studies measured colonization and oth-
ers examined infection. Units of measurement were also
variable (e.g., number of isolates, percentage of isolates,
number of cases, and number of cases per time period).
Gram-positive Bacteria
Data for gram-positive bacteria were very limited. One
study provided strong evidence that restricting ceftazidime
in a hematology unit was associated with significant reduc-
tion in risk for colonization by VRE (27). However, reduc-
tion of cephalosporin use in a hospital was not associated
with any change in the prevalence of VRE isolates (17). A
third study targeted at VRE showed that implementation of
a vancomycin order form had no significant impact on
vancomycin prescribing, with a trend in the unintended
direction (22). Two studies report effects on MRSA preva-
lence (17,21). Our segmented regression analysis showed
no significant change in response to a reduction in use of
third-generation cephalosporins (online Appendix Table),
although 1 of the reports claimed that a change did occur
(21).
Discussion
Our primary conclusion is that 4 of the 16 studies pro-
vided strong evidence that changes in prescribing antimi-
crobial drugs to hospital inpatients can improve microbial
outcomes (17,27,30,31). Eight of the remaining studies
provided some evidence that antimicrobial drug–prescrib-
ing interventions can improve microbial outcomes, but
flaws in their design indicated that there were plausible
alternative explanations for the results (18–20,23,
24,26,28,29). The remaining 4 studies were unequivocally
negative (21,22,25,32).
Estimation of overall effect size was only possible for
reduction in CDAD, where the evidence suggested that
restriction of clindamycin or third-generation
cephalosporins resulted in an immediate reduction in
prevalence by 15 cases per quarter, with an additional sus-
tained reduction by 3 cases per quarter. Prevalence is usu-
ally adjusted for clinical activity, e.g., cases per 1,000
admissions per quarter (7), but only 1 study provided this
information (17). Furthermore, potentially important dif-
ferences in the case definitions of CDAD occurred
between the studies in our review.
Finding valid studies required painstaking analysis of a
huge volume of literature, most of which is fundamentally
flawed (16). The included studies could be dramatically
improved by following guidelines for standardized report-
ing (15). In particular, the unequal duration of postinterven-
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Figure. A) Standardized immediate and sustained effects for
Clostridium difficile–associated diarrhea. B) Standardized immedi-
ate and sustained effects for resistant gram-negative bacteria.tion phases made it difficult to reliably compare the sus-
tained effects of interventions, these being the most impor-
tant outcome measures. The short and unequal duration of
preintervention phases provides limited information about
underlying preintervention trends. To understand how
much of a change in prescribing is required to change out-
come, the intervention must be independent of other control
measures and be accompanied by reliable data about both
prescribing and microbial outcomes.
Only 1 of the interventions was designed to reduce
overall exposure to antimicrobial drugs (31). All of the
other studies targeted the choice of antimicrobial drug
(e.g., by restricting access to third-generation cephalo-
sporins in favor of drugs recommended by the hospital
antimicrobial drug policy) but did not aim to shorten the
duration of treatment. This intervention (31) shortened the
duration of antimicrobial drug treatment for ICU patients
at low risk for ventilator-associated pneumonia. This study
was conducted in an ICU with adult patients. However, the
same principle of using clinical scores to identify low-risk
patients, in whom antimicrobial drug therapy could be
stopped, has been developed in other clinical settings
(33–35), and the impact on microbiologic outcomes should
be investigated.
None of the studies provided evidence for cost-effec-
tiveness or clinical outcome. The study designs likely did
not have sufficient power to measure these outcomes. Few
studies provided data about multiple microbiologic species
and 1 of these endpoints (incidence of cefotaxime-resistant
Acinetobacter spp.) was opposite to that which was expect-
ed (21). Future studies should provide more data about cost
and clinical outcomes. Notably, evidence is needed to show
that interventions do not have adverse outcomes.
The potential for the success of antimicrobial drug inter-
ventions likely varies by organism (36,37). Antimicrobial
drugs are likely to play a large role in the selection of enter-
obacteria expressing extended-spectrum β-lactamases, a
minimal role in the selection and transmission of MRSA,
and an intermediate role in VRE. However, the available
evidence is not sufficient to investigate these hypotheses.
Implications for Practice
The evidence supports the theory that limiting the use
of specific antimicrobial drugs will reduce the prevalences
of resistant gram-negative bacteria and CDAD. For gram-
positive bacteria, there is a lack of evidence rather than
evidence of no effect. Hospitals would like to know how
much they should limit their antimicrobial drug prescrip-
tions and what is the minimum that will show a real effect.
Unfortunately, the available evidence is too limited to pro-
vide definitive answers to these issues. Thus, hospitals
must estimate the effect of their own interventions. The
good news is that the data required for ITS analysis of the
incidences of drug-resistant bacteria or CDAD should be
readily available in most hospitals. Healthcare providers
need to invest in data analysis so that evaluation of antimi-
crobial drug control in hospitals becomes a routine meas-
ure of the quality of care rather than a research project.
Standardized reporting of outbreaks and interventions
to control the incidence of antimicrobial drug resistance or
hospital-acquired infection would greatly enhance the abil-
ity to combine results from hospitals in metaanalyses. Key
issues include full description of other infection control
measures, consistent and reproducible case definitions, the
length of preintervention and postintervention phases, and
the intervals between data points (15). Ideally, data should
be made available in a way that allows reanalysis and,
where appropriate, metaanalysis. Metaanalysis of single
hospital studies is no substitute for good multicenter stud-
ies, but it could be used to provide some evidence of repro-
ducibility and thus to prioritize targets for definitive trials.
Priorities for Research
The research agenda needs to move to multicenter stud-
ies with randomized allocation to interventions. This will
provide better evidence of external validity as well as the
power to measure cost-effectiveness and exclude impor-
tant unintended adverse clinical outcomes. Development
and pilot testing of the effectiveness of clinical decisions
for reducing unnecessary exposure to antimicrobial drugs
should be a priority for research in hospitals.
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